Annual CFF
$93.86 M
-$252.31 M-72.89%
December 31, 2023
Summary
- As of February 7, 2025, RNA annual cash flow from financing activities is $93.86 million, with the most recent change of -$252.31 million (-72.89%) on December 31, 2023.
- During the last 3 years, RNA annual CFF has fallen by -$178.17 million (-65.50%).
- RNA annual CFF is now -72.89% below its all-time high of $346.17 million, reached on December 31, 2022.
Performance
RNA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$342.46 M
-$104.26 M-23.34%
September 1, 2024
Summary
- As of February 7, 2025, RNA quarterly cash flow from financing activities is $342.46 million, with the most recent change of -$104.26 million (-23.34%) on September 1, 2024.
- Over the past year, RNA quarterly CFF has increased by +$342.42 million (+856060.00%).
- RNA quarterly CFF is now -23.34% below its all-time high of $446.72 million, reached on June 30, 2024.
Performance
RNA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$1.21 B
+$342.42 M+39.45%
September 1, 2024
Summary
- As of February 7, 2025, RNA TTM cash flow from financing activities is $1.21 billion, with the most recent change of +$342.42 million (+39.45%) on September 1, 2024.
- Over the past year, RNA TTM CFF has increased by +$904.90 million (+296.08%).
- RNA TTM CFF is now at all-time high.
Performance
RNA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RNA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -72.9% | +10000.0% | +296.1% |
| 3 y3 years | -65.5% | +120.7% | +675.7% |
| 5 y5 years | +1724.7% | +10000.0% | +1256.6% |
RNA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -72.9% | at low | -23.3% | >+9999.0% | at high | +1189.7% |
| 5 y | 5-year | -72.9% | +5.2% | -23.3% | >+9999.0% | at high | >+9999.0% |
| alltime | all time | -72.9% | +1724.7% | -23.3% | >+9999.0% | at high | >+9999.0% |
Avidity Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $342.46 M(-23.3%) | $1.21 B(+39.4%) |
| Jun 2024 | - | $446.72 M(+14.7%) | $868.10 M(+88.6%) |
| Mar 2024 | - | $389.44 M(+1121.2%) | $460.35 M(+390.4%) |
| Dec 2023 | $93.86 M(-72.9%) | $31.89 M(>+9900.0%) | $93.86 M(-69.3%) |
| Sep 2023 | - | $40.00 K(-99.9%) | $305.63 M(-11.5%) |
| Jun 2023 | - | $38.97 M(+69.7%) | $345.21 M(+0.1%) |
| Mar 2023 | - | $22.96 M(-90.6%) | $345.02 M(-0.3%) |
| Dec 2022 | $346.17 M(+96.3%) | $243.65 M(+515.0%) | $346.17 M(+180.9%) |
| Sep 2022 | - | $39.62 M(+2.2%) | $123.23 M(-48.4%) |
| Jun 2022 | - | $38.78 M(+60.8%) | $238.78 M(+19.1%) |
| Mar 2022 | - | $24.11 M(+16.4%) | $200.41 M(+13.7%) |
| Dec 2021 | $176.32 M | $20.71 M(-86.7%) | $176.32 M(+13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $155.17 M(>+9900.0%) | $156.05 M(<-9900.0%) |
| Jun 2021 | - | $413.00 K(+2329.4%) | -$466.00 K(-100.2%) |
| Mar 2021 | - | $17.00 K(-96.2%) | $270.73 M(-0.5%) |
| Dec 2020 | $272.04 M(+204.9%) | $450.00 K(-133.4%) | $272.04 M(-20.8%) |
| Sep 2020 | - | -$1.35 M(-100.5%) | $343.41 M(-0.2%) |
| Jun 2020 | - | $271.61 M(>+9900.0%) | $344.05 M(+296.7%) |
| Mar 2020 | - | $1.32 M(-98.2%) | $86.73 M(-2.8%) |
| Dec 2019 | $89.23 M(+1634.7%) | $71.82 M(<-9900.0%) | $89.23 M(+412.6%) |
| Sep 2019 | - | -$712.00 K(-105.0%) | $17.41 M(-3.9%) |
| Jun 2019 | - | $14.30 M(+274.1%) | $18.12 M(+374.1%) |
| Mar 2019 | - | $3.82 M | $3.82 M |
| Dec 2018 | $5.14 M | - | - |
FAQ
- What is Avidity Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Avidity Biosciences?
- What is Avidity Biosciences annual CFF year-on-year change?
- What is Avidity Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Avidity Biosciences?
- What is Avidity Biosciences quarterly CFF year-on-year change?
- What is Avidity Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Avidity Biosciences?
- What is Avidity Biosciences TTM CFF year-on-year change?
What is Avidity Biosciences annual cash flow from financing activities?
The current annual CFF of RNA is $93.86 M
What is the all time high annual CFF for Avidity Biosciences?
Avidity Biosciences all-time high annual cash flow from financing activities is $346.17 M
What is Avidity Biosciences annual CFF year-on-year change?
Over the past year, RNA annual cash flow from financing activities has changed by -$252.31 M (-72.89%)
What is Avidity Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of RNA is $342.46 M
What is the all time high quarterly CFF for Avidity Biosciences?
Avidity Biosciences all-time high quarterly cash flow from financing activities is $446.72 M
What is Avidity Biosciences quarterly CFF year-on-year change?
Over the past year, RNA quarterly cash flow from financing activities has changed by +$342.42 M (+856060.00%)
What is Avidity Biosciences TTM cash flow from financing activities?
The current TTM CFF of RNA is $1.21 B
What is the all time high TTM CFF for Avidity Biosciences?
Avidity Biosciences all-time high TTM cash flow from financing activities is $1.21 B
What is Avidity Biosciences TTM CFF year-on-year change?
Over the past year, RNA TTM cash flow from financing activities has changed by +$904.90 M (+296.08%)